According to OptiNose, the company has completed a Series C-1 round of financing that will support development of its second product, OPN-375 intranasal fluticasone. The company, along with partner Avanir, submitted an NDA for its first product, AVP-825 intranasal sumatriptan for the treatment of migraine, in January 2014. According to the company, its … [Read more...] about OptiNose raises funds for development of intranasal fluticasone
Business
Alexza announces plans for development of inhaled ropinirole
Alexza Pharmaceuticals has announced that it will develop Staccato versions of ropinirole, a dopamine agonist, for the treatment of restless leg system (AZ-008) and for the treatment of hypomobility during OFF episodes in Parkinson's disease (AZ-009). The Staccato system uses heat to aerosolize pure API for inhalation. The company said that it also plans to begin a … [Read more...] about Alexza announces plans for development of inhaled ropinirole
Mystic Pharmaceuticals gets notice of allowance for dry powder delivery tech patent
Mystic Pharmaceuticals has announced that the United States Patent and Trade Office issued a Notice of Allowance for the company's patent application titled “Medical Devices For Dispensing Powders” (application #13/433,586). The technology is an extension of the company's VRx2 delivery platform and can be used for nasal, buccal, sublingual and opthalmic powder … [Read more...] about Mystic Pharmaceuticals gets notice of allowance for dry powder delivery tech patent
AstraZeneca acquires rights to Almirall’s respiratory business
AstraZeneca will pay $875 million initially, plus up to an additional $1.22 billion to acquire development and commercialization rights to Almirall's entire respiratory drug business. Almirall's respiratory products include the Eklira/Bretaris/Tudorza aclidinium DPI, an aclidinium/formoterol DPI, and several other inhaled drugs in development. The company's inhalation … [Read more...] about AstraZeneca acquires rights to Almirall’s respiratory business
Lightlake files IND for intranasal naloxone, gets additional NIDA funding
Lightlake Therapeutics has announced that it filed an investigational new drug application for its intranasal naloxone therapy for the reversal of opioid overdose. The company also said that it has received additional funding from the National Institute on Drug Abuse (NIDA) for a new clinical trial of the product. Lightlake recently said that it had signed a … [Read more...] about Lightlake files IND for intranasal naloxone, gets additional NIDA funding
ProStrakan to acquire Archimedes Pharma, PecFent nasal spray
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has announced that it will acquire PecFent fentanyl nasal spray manufacturer Archimedes Pharma for £230 million in cash. Archimedes, which is based in Reading, UK, received European marketing approval for PecFent in 2011. Archimedes sold its US business and the US version of PecFent, marketed as Lazanda, to Depomed in … [Read more...] about ProStrakan to acquire Archimedes Pharma, PecFent nasal spray
Merck sues Teva over mometasone furoate nasal spray
Following the submission by Teva of an ANDA for a generic mometasone furoate nasal spray, Merck has filed suit in the US District Court alleging infringement of US patent 6,127,353. The patent is due to expire in October 2017. In June 2012, a US District Court judge upheld the validity of the patent in a suit by Merck against Apotex but ruled that Merck had … [Read more...] about Merck sues Teva over mometasone furoate nasal spray
Biotie returns intranasal diazepam rights to Neurelis
Biotie Therapeutics has decided not to exercise its option to purchase Neurelis and is returning the rights to Neurelis's lead product, NRL-1 intranasal diazepam for the treatment of epileptic seizures. Biotie paid $1 million for the option to purchase Neurelis in June 2013. Under the deal, Biotie will still participate in any future revenues from the product to … [Read more...] about Biotie returns intranasal diazepam rights to Neurelis
Aegis gets patent for stable insulin for intranasal delivery, announces intranasal octreotide license availability
The US Patent and Trade Office (USPTO) has awarded Aegis Therapeutics US Patent No. 8,772,231 for "dramatically stabilized insulin formulations suitable for metered nasal spray delivery or injection based upon Aegis’ patented Intravail transmucosal absorption enhancer and ProTek protein stabilization technologies," the company said. According to Aegis, the company … [Read more...] about Aegis gets patent for stable insulin for intranasal delivery, announces intranasal octreotide license availability
Lightlake signs manufacturing contract for its intranasal naloxone
According to Lightlake Therapeutics, the company has signed a contract with a manufacturer for commercial production of its intranasal naloxone for the reversal of opioid overdose. In December 2013, the company announced positive initial results from a PK study of the product and said that it planned to submit an NDA in 2014. Lightlake CEO Roger Crystal commented, … [Read more...] about Lightlake signs manufacturing contract for its intranasal naloxone